Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence
Neoadjuvant immunotherapy appears to be a feasible and safe approach in patients with resectable HCC, achieving moderate pathological responses and high resection rates.
Authors
- Alessandro Vanoli (ORCID: https://orcid.org/0000-0002-2976-7032)
- Barbara Oliviero (ORCID: https://orcid.org/0000-0002-0532-4608)
- Marcello Maestri (ORCID: https://orcid.org/0000-0002-5693-9151)
- Francesca Berton
- Stefania Mantovani (ORCID: https://orcid.org/0000-0002-5885-2842)
- Valentina Ravetta
- Salvatore Corallo (ORCID: https://orcid.org/0000-0002-6672-0233)
- Laura Maiocchi (ORCID: https://orcid.org/0000-0002-5075-5626)
- Ottavia Cicerone (ORCID: https://orcid.org/0009-0004-9712-2553)
Institutions
- University of Pavia (IT)
Publication Details
- Journal
- World Journal of Clinical Oncology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.5306/wjco.v16.i10.110511
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00